VANCOUVER, British Columbia, Jan. 24, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd., (Pink Sheets:IMMFF) a company in the business of development and commercialization of immune therapies, announced today that its newly acquired business, Immunitor Inc., has published interim data from the ongoing Phase IIb imm01 clinical trial of V5 in tuberculosis (including multidrug resistant TB, MDR-TB) conducted at its second site in Ukraine. The results from the Department of Phtysiatry and Pulmonology of Kharkov Medical University appeared in peer-reviewed Journal of Immune Based Therapies and Vaccines - an open access journal from BioMed Central (http://www.jibtherapies.com/content/9/1/3/abstract). The principal investigator of the study is Professor Svetlana Zaitzeva – an established expert in immunotherapy of tuberculosis (TB) and the editor of the authoritative book "Phtysiatry".
